TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24521776
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg/d)
Study: 10971307
Drug: Asimadoline 10
Normalized name: Asimadoline
DrugBank: Asimadoline (DB05104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asimadoline 10 mg
Study: 6812685
Drug: Aspirin 40
Normalized name: aspirin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 40 mg every 48 hours
Study: 21550310
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate (500 mg/day for 1 week, then once a week to complete 12 weeks)
Study: 30496510
Drug: Pulsed Ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Ultrasound (PUS) treatment
Study: 27918196
Drug: Oral riboflavin
Normalized name: riboflavin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral riboflavin incorporated into active treatment pills
Study: 19238488
Drug: Varenicline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline with behavioral smoking cessation treatment
Study: 17445101
Drug: Early Treatment
Normalized name: Clearly It!
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Treatment (ET) with almotriptan 12.5 mg, treated at earliest onset of headache pain (within 1 hour)
Study: 17445101
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (ST) with almotriptan 12.5 mg, treated when headache pain intensity is moderate or severe
Study: 17445101
Drug: Early Treatment
Normalized name: Clearly It!
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Treatment (ET) subgroup treating headache pain within 1 hour of onset
Study: 17445101
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (ST) subgroups treating within 1 hour versus greater than 1 hour after headache onset
Study: 17445101
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events in Early Treatment (ET) group
Study: 17445101
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events in Standard Treatment (ST) group
Study: 8087439
Drug: Lung Cancer
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung Cancer Symptom Scale (LCSS) administered at baseline, day 29, and day 71
Study: 2767747
Drug: Intrathecal pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal pentazocine (0, 1, 2, 3, 4, and 5 mg) along with 1% bupivacaine
Study: 20442758
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days on/2 days off treatment
Study: 12034036
Drug: Intermediate-dose interferon-alpha2b
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose interferon-alpha2b
Study: 12034036
Drug: Low-dose and
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose and intermediate-dose interferon-alpha2b
Study: 16467232
Drug: Low-fat dietary
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat dietary pattern intervention (tumor hormone receptor characteristics)
Study: 11005044
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage right unilateral ECT
Study: 11005044
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage right unilateral ECT
Study: 3528889
Drug: Piracetam (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (2.4 to 9.9 g/day)
Study: 24194899
Drug: Sodium hypochlorite
Normalized name: Sodium hypochlorite
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium hypochlorite (liquid bleach) for household water treatment
Study: 24194899
Drug: No water
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [70% alcohol hand sanitizer (no water)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No water treatment (Control)
Study: 3542451
Drug: Intraperitoneal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal insulin above transverse mesocolon (0.2 IU/kg)
Study: 3542451
Drug: Intraperitoneal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal insulin below transverse mesocolon (0.2 IU/kg)
Study: 3542451
Drug: Intramuscular insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular insulin (0.2 IU/kg)
Study: 3542451
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (0.2 IU/kg)
Study: 20645484
Drug: Spinal-intravenous anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal-intravenous anesthesia and analgesia
Study: 20645484
Drug: General-intravenous anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General-intravenous anesthesia and analgesia
Study: 11099374
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + Cr+3 (CHO plus chromium picolinate 400 mg)
Study: 8297447
Drug: naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (2 x 0.1 mg)
Study: 26874885
Drug: Eribulin (1·4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin (1·4 mg/m² intravenously on days 1 and 8)
Study: 26874885
Drug: Dacarbazine (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (850 mg/m², 1000 mg/m², or 1200 mg/m² intravenously on day 1)
Study: 12795749
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg b.i.d
Study: 1650106
Drug: Antidepressants (desipramine/petytyl)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (desipramine/petytyl) and incazane
Study: 23374372
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy alone (n = 25)
Study: 21225293
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg rocuronium
Study: 17228345
Drug: Milk (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (1.5 l/day)
Study: 14732826
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to hemodialysis guidelines and modifiable practices (dialysis dose, phosphate control, improved anemia, partial correction of serum albumin, reduced interdialytic weight gain, less use of catheters for vascular access)
Study: 14732826
Drug: Having albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Having albumin <3.5 g/dl
Study: 9842820
Drug: Prophylactic metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic metoprolol (maximal dose of 10 mg)
Study: 7488278
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cM-T412
Study: 7488278
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg cM-T412
Study: 8128188
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cM-T412
Study: 2570001
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg acrivastine three times daily
Study: 25985245
Drug: EUS-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUS-guided therapy with adalimumab (ADA)
Study: 21214940
Drug: IPTc (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPTc (monthly IPTc with a single dose of sulphadoxine/pyrimethamine (SP) plus three doses of amodiaquine (AQ))
Study: 16478746
Drug: Weekly darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly darbepoetin alfa (2.25-microg/kg)
Study: 8260564
Drug: Intravenous adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous adrenaline infusions
Study: 3518773
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg once daily + Indomethacin 50 mg twice daily
Study: 29469206
Drug: Sacubitril-valsartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril-valsartan treatment for 3 months
Study: 27591767
Drug: reduced-dose/IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: reduced-dose/IR
Study: 27591767
Drug: standard-dose/FBP
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-dose/FBP
Study: 8821311
Drug: Daily lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lithium dosing (700 mg)
Study: 8821311
Drug: Alternate-day lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day lithium dosing (1200 mg)
Study: 8002850
Drug: Cholesterol reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol reduction treatment
Study: 3937665
Drug: Levonorgestrel contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel contraceptive implants (NORPLANT)
Study: 31219771
Drug: Nonselective β-adrenergic
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective β-adrenergic blockade (40 mg propranolol)
Study: 23547209
Drug: Belimumab 4
Normalized name: belimumab 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab 4 mg/kg
Study: 23547209
Drug: Belimumab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (any dose) in open-label extension
Study: 23547209
Drug: Placebo switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo switched to belimumab 10 mg/kg in extension
Study: 21470404
Drug: K-1 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-1 mmol/l
Study: 19817753
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids + Vitamin D(3)
Study: 14872179
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of varicella vaccine
Study: 14872179
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of varicella vaccine
Study: 11434826
Drug: 90 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/kg per day for 5 days (n = 398)
Study: 11434826
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg per day for 10 days (n = 397)
Study: 3063288
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HCTZ with amiloride (Group 2)
Study: 25552906
Drug: Selexipag (400-1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag (400-1,600 μg, administered twice daily for 21 days)
Study: 25552906
Drug: Moxifloxacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (single oral 400 mg dose on day 2 or 24)
Study: 15496220
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl 5 mg once daily for 15 days
Study: 15496220
Drug: Sertraline HCl
Normalized name: sertraline HCl
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline HCl 50 mg once daily for 5 days followed by 100 mg once daily for 10 days
Study: 15496220
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of donepezil HCl and sertraline HCl
Study: 15496220
Drug: Sertraline HCl
Normalized name: sertraline HCl
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline HCl only
Study: 8113482
Drug: Sexual assault
Normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual assault prevention program (treatment group)
Study: 31413088
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg iron as ferrous sulfate on alternate days
Study: 31413088
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg iron as ferrous sulfate on consecutive days
Study: 31413088
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg iron as ferrous sulfate on consecutive days
Study: 31413088
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg iron as ferrous sulfate on alternate days vs 200 mg on consecutive days
Study: 29669086
Drug: PA +
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA + CBT‐P group (physical activity plus cognitive-behavioral therapy for pain)
Study: 10661483
Drug: Augmented blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented blood flow and saline flush (200‐250 ml/min and 100 ml twice hourly)
Study: 3531308
Drug: Ranitidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine treatment in second 4-week period for 124 unhealed patients
Study: 19248105
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injection (2.5 ml)
Study: 19248105
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (2.5 ml)
Study: 11723147
Drug: Normal-carbohydrate meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-carbohydrate meal (65 g)
Study: 11723147
Drug: High-carbohydrate meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate meal (125 g)
Study: 9340918
Drug: Beta-blockers and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers and platelet aggregation inhibitors
Study: 3565242
Drug: Computer-aided dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-aided dosing (Bayesian forecasting technique)
Study: 3565242
Drug: Control (unaided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (unaided physician dosing)
Study: 3565242
Drug: Lidocaine concentrations
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine concentrations greater than 2 mg/L
Study: 31852769
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g FMT
Study: 31852769
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g FMT
Study: 22718671
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Valeriana Officinalis L. (765 mg/day)
Study: 22718671
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 mg/day)
Study: 19384840
Drug: Olmesartan (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (initial dose 5 mg, increased to 10 mg, 20 mg, and 40 mg over 16 weeks)
Study: 14623807
Drug: Water ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water ingestion (16 oz / 473 mL) 5 minutes before tilt-table testing
Study: 8783054
Drug: No washing
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No washing (control group), 30s washing 2X daily for 7 days
Study: 22325733
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 1200 mg
Study: 8698375
Drug: Topical clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clotrimazole applied twice daily for 7 days
Study: 1519716
Drug: Ibuprofen/codeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/codeine combination (400 mg ibuprofen/25.6 mg codeine phosphate)
Study: 1519716
Drug: Paracetamol/codeine/caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/codeine/caffeine combination (1 g paracetamol/16 mg codeine phosphate/60 mg caffeine)
Study: 6503363
Drug: 360 J
Normalized name: Vitamin J
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 360 J (maximal energy dose available in most defibrillators)
Study: 19053970
Drug: Open sequential
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open sequential treatment protocol (augmentation with lithium, switch to a monoamine oxidase inhibitor or ECT)
Study: 19053970
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with lithium
Study: 8362305
Drug: Halofantrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (3 doses of 500 mg at 6 hour intervals)
Study: 8362305
Drug: Mefloquine (divided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (divided doses of 1,250 mg or 1,500 mg based on weight)
Study: 21567070
Drug: sivelestat (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sivelestat (0.2 mg/kg/h from induction of anesthesia to post-operative day 1)
Study: 15328756
Drug: BN165 (Ginkor
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN165 (Ginkor Fort) 3 capsules per day
Study: 11002713
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of alfentanil at T5-7 (group T)
Study: 9149197
Drug: Tensilon 10
Normalized name: Tensilon 10 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tensilon 10 mg i.v.
Study: 3766854
Drug: Amoscanate 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoscanate 1 mg/kg
Study: 6134827
Drug: Weekly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sessions
Study: 30354784
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (Zilver PTX stent implantation without cilostazol)
Study: 25566620
Drug: Yindan Xinnaotong
Normalized name: Lindane
DrugBank: Lindane (DB00431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yindan Xinnaotong Soft Capsule (YXSC)
Study: 30650286
Drug: Naoxintong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxintong Capsule (NC)
Study: 18215592
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors or clopidogrel
Study: 9124201
Drug: TAE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAE plus 5'-DFUR (400 mg/day)
Study: 8087578
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation treatment modalities
Study: 8087578
Drug: Treatment protocols
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment protocols
Study: 21539702
Drug: Transforaminal injection
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal injection of steroids (TFIS)
Study: 17038949
Drug: COX‐2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2 inhibitor in addition to narcotics (Experimental)
Study: 1804649
Drug: SR 33557
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 33557 (100 mg)
Study: 29202563
Drug: Nebulized hyaluronic
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized hyaluronic acid (HA) via Spray-sol, twice a day for 10 days (T1)
Study: 29202563
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline nebulized via Spray-sol, twice a day for 10 days (T2)
Study: 19668121
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 50 mg/day
Study: 18779774
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 300 mg/day
Study: 17602036
Drug: Milrinone (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (bolus and infusion before cardiopulmonary bypass until skin closure)
Study: 9542478
Drug: Zolmitriptan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (all doses)
Study: 8566267
Drug: Pulsatile administration
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile administration of hMG
Study: 26413500
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg DHA supplementation
Study: 25168665
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/d + Pregabalin 300 mg/d
Study: 25168665
Drug: Combination/high-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination/high-dose therapy
Study: 23732189
Drug: High-dose monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose monotherapy
Study: 9726387
Drug: OAM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM (omeprazole 20 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Study: 10651664
Drug: OMC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 500 mg b.d.)
Study: 10651664
Drug: Pre-treatment metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-treatment metronidazole resistance
Study: 331920
Drug: Betahistine 24
Normalized name: betahistine 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 24 mg daily
Study: 31944221
Drug: Dasatinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (80 mg/m2 daily)
Study: 31944221
Drug: Imatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (300 mg/m2 daily)
Study: 25321162
Drug: 2.5% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% mannitol + 10 mg scopolamine butylbromide
Study: 25321162
Drug: 2.5% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% mannitol + 20 mg scopolamine butylbromide
Study: 22057498
Drug: HPPH-PDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPPH-PDT with 3 mg/m2 HPPH (light dose of 150 J/cm at 48 hours)